Estuardo Aguilar-Cordova
Fondateur chez CANDEL THERAPEUTICS, INC.
Fortune : 28 M $ au 31/05/2024
Postes actifs de Estuardo Aguilar-Cordova
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CANDEL THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/01/2002 | - |
| Fondateur | 01/01/2002 | - | |
| Directeur Général | 01/01/2002 | 01/09/2020 | |
| Directeur Technique/Scientifique/R&D | 01/09/2020 | 07/02/2022 |
Historique de carrière de Estuardo Aguilar-Cordova
Anciens postes connus de Estuardo Aguilar-Cordova
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Harvard Medical School | Corporate Officer/Principal | - | - |
Nemucore Medical Innovations, Inc.
 Nemucore Medical Innovations, Inc. Pharmaceuticals: MajorHealth Technology Nemucore Medical Innovations, Inc. is a clinical development company. It specializes in the development and commercialization of molecularly targeted therapeutics for the treatment of multi-drug resistant cancers with an emphasis on women's oncology. The company was founded by Timothy P. Coleman, Yuri Lvov, Vladimir Torchilin and Mansoor Amiji in 2008 and is headquartered in Wellesley, MA. | Directeur/Membre du Conseil | - | - |
| Corporate Officer/Principal | - | - |
Formation de Estuardo Aguilar-Cordova
| California State University-Bakersfield | Undergraduate Degree |
| University of California, Davis | Doctorate Degree |
| Universidad Del Valle De Guatemala | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
| Guatemala | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 2 |
Sectorielle
| Consumer Services | 5 |
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. Pharmaceuticals: MajorHealth Technology Nemucore Medical Innovations, Inc. is a clinical development company. It specializes in the development and commercialization of molecularly targeted therapeutics for the treatment of multi-drug resistant cancers with an emphasis on women's oncology. The company was founded by Timothy P. Coleman, Yuri Lvov, Vladimir Torchilin and Mansoor Amiji in 2008 and is headquartered in Wellesley, MA. | Health Technology |
- Bourse
- Insiders
- Estuardo Aguilar-Cordova
- Expérience
